Methylene Blue and Bipolar Disorder: Examining the Clinical Research

The short version

Methylene blue has been studied in bipolar disorder longer than most people realize, starting in the 1970s as investigators looked for alternatives and adjuncts to lithium. The total evidence base is small: one open case series, two historical controlled trials, and one modern randomized crossover study. The consistent signal across them is improvement in depressive and residual symptoms when methylene blue was added to existing treatment. No study showed an antimanic effect, and no study produced a clear mania-switch signal, though the samples were far too small to settle the switch question. Anyone evaluating this compound should read these as adjunctive-treatment studies, not monotherapy evidence, and should weigh the interaction cautions before drawing any practical conclusions.

Why bipolar disorder attracted attention early

The rationale was never that methylene blue looked like a conventional mood stabilizer. Structurally it resembles phenothiazines, and early investigators hypothesized it might reduce plasma vanadate to a less active form, altering sodium-potassium ATPase activity implicated in mood cycling. As a proof of concept, Naylor and colleagues treated two continuously cycling patients and observed longer euthymic periods, which motivated everything that followed. Howland's historical account of methylene blue in psychiatry places this work in context, tracing the compound from phenothiazine precursor to experimental psychotropic.

Later mechanistic work reframed the rationale around mitochondrial function and redox balance. Mitochondrial dysfunction has been implicated in bipolar disorder through family studies, postmortem gene-expression findings, and animal models such as the POLG1 mutant mouse, whose bipolar-like phenotype responds partly to lithium. Alda's 2019 review of methylene blue in neuropsychiatric disorders argues that the compound's ability to shuttle electrons past blocked points in the electron transport chain, reducing reactive oxygen species leakage, gives it heuristic value as a mitochondrial modulator. A separate review of methylene blue as an antidepressant candidate adds MAO-A inhibition, nitric oxide synthase and guanylate cyclase blockade, and anti-inflammatory effects to the mechanistic picture. Mechanisms are hypotheses, though. The clinical question is what the trials measured, and under what conditions.

The trials, one by one

Narsapur and Naylor case series: refractory patients, open treatment

The first report was an uncontrolled series of 24 chronically or severely ill patients given add-on methylene blue at 200 or 300 mg daily for periods ranging from days to over a year. Nineteen had bipolar (manic-depressive) illness, and 14 of those 19 were judged definitely improved, a 74 percent response proportion. Three patients whose bipolar diagnosis was considered uncertain did not respond.

Treat this as hypothesis generation, not efficacy data. There was no randomization, no blinding, no standardized scale, and background medications were incompletely reported. A 74 percent figure from an open series in refractory patients reflects observer judgment and selection as much as pharmacology.

Naylor et al. 1986: two-year crossover prophylaxis with lithium

This was the most ambitious of the early studies: a two-year, double-blind randomized crossover trial in 31 patients with bipolar illness. Each participant was to receive 300 mg daily for one year and 15 mg daily for the other year, in random order. The 15 mg dose served as the comparator, chosen largely because urine discoloration made a truly inert placebo impossible to blind. Critically, every participant remained on lithium throughout, so this was adjunctive prophylaxis from the start.

Seventeen of the 31 completed both years. Among completers, depressive symptoms were significantly less severe during the 300 mg year than during the 15 mg year, while manic symptom severity did not differ between doses. Admission rates were reported as lower during the trial than before it, though Alda's later review notes this applied even during the 15 mg periods, which complicates interpretation. The investigators themselves flagged the weaknesses: small sample, 45 percent attrition, simple rating scales, doubtful blinding, and uncertainty over whether 15 mg was pharmacologically inert. That last concern proved prescient, as described below.

Naylor low-dose depression study: why the "placebo" may have been active

A subsequent three-week, double-blind comparison tested 15 mg daily against inert placebo in 35 patients with severe depressive illness and found methylene blue significantly superior. This was a unipolar-predominant depression cohort rather than a bipolar trial, so it belongs in the general depression evidence rather than the bipolar column. Its importance for bipolar readers is methodological: the 15 mg dose used as a comparator in both crossover trials had itself beaten inert placebo. Any treatment contrast measured against 15 mg therefore likely understates the full difference versus nothing, while also meaning neither historical trial had a true placebo arm.

Alda et al. 2017: the modern adjunctive crossover trial

The most rigorous study to date randomized 37 adults with bipolar I or II disorder and residual symptoms to methylene blue 195 mg daily versus 15 mg daily, each for 13 weeks in crossover fashion. This was explicitly adjunctive treatment: every participant had been stable on lamotrigine for at least three months and continued it, with lithium, divalproex, antipsychotics, and antidepressants permitted at stable doses. The trial is indexed at PubMed 27284082. Baseline symptoms were mild to moderate, with mean Hamilton depression scores around 7.6 and Montgomery-Asberg scores near 12.7.

Results favored 195 mg on depression and anxiety measures. Among completers, effect sizes were approximately 0.71 on the Hamilton depression scale, 0.80 on the Montgomery-Asberg scale, and 0.79 on the Hamilton anxiety scale, each statistically significant, with the last-observation-carried-forward analysis in all 37 patients yielding similar significant results. Mania scores stayed low and stable with no treatment effect, and the cognitive battery showed no significant benefit on verbal memory, executive function, or attention measures. Ten participants withdrew for reasons including worsening bipolar symptoms, anxiety, fluid retention, and consent withdrawal. Adverse effects were mainly transient urinary burning, gastrointestinal upset, and headache.

Clinical-trial table: what was actually tested

Reading the pattern honestly

Three observations survive contact with the limitations. First, the direction of effect is consistent: depressive and residual symptoms improved with the higher dose in both controlled bipolar studies, with moderate effect sizes in the modern trial. Second, nothing in this literature supports an antimanic claim. The dedicated mania trial was negative, and the crossover studies found no mania difference, which is absence of antimanic efficacy, not evidence of mood stabilization in both poles. Third, no treatment-emergent mania signal appeared, but that statement carries little weight. Baseline mania scores were near zero and the exposed samples numbered in the dozens, so these studies could not have detected a switch risk of clinically relevant size. The correct phrasing is that no switch signal was observed, not that switch risk was excluded.

Two methodological problems deserve emphasis because they cut across the whole evidence base. Blinding was structurally compromised in every crossover study, since methylene blue discolors urine and the low-dose comparator was chosen precisely to mimic that effect while assumed inactive. And that assumption failed: the low dose beat inert placebo in depression, meaning the pivotal contrasts were dose comparisons between two potentially active regimens rather than drug-versus-placebo tests. Effect sizes measured this way are difficult to interpret and cannot be pooled with standard placebo-controlled antidepressant trials.

Scope discipline matters here. These are bipolar trials with bipolar endpoints, and they should not be mixed with evidence from other populations. Readers interested in adjacent literatures should consult the anxiety findings, the cognition research, and the safety and interaction profile separately, since each involves different study designs and risk considerations.

Safety context for bipolar polypharmacy

Two cautions are directly relevant to bipolar patients, who are commonly prescribed serotonergic agents. Methylene blue and its metabolite azure B are potent reversible MAO-A inhibitors, and co-administration with SSRIs, SNRIs, and other serotonergic drugs can precipitate serotonin syndrome. Nearly all published toxicity cases involved intravenous methylene blue, and the modern bipolar trial allowed antidepressants in 20 of 37 participants without a serotonergic event, but that small experience does not override the interaction warning, and current labeling for the intravenous product carries a boxed warning on this point. Separately, glucose-6-phosphate dehydrogenase deficiency is a contraindication because methylene blue can trigger hemolysis, and the modern trial excluded such patients. Anyone combining these agents needs clinician supervision; this is pharmacology with real failure modes, not a benign supplement interaction.

Where this leaves the question

Methylene blue in bipolar disorder is a small, old, suggestive literature plus one respectable modern pilot. The honest summary: adjunctive methylene blue at roughly 195 to 300 mg daily repeatedly eased depressive and residual symptoms in small samples, showed an anxiety signal once, showed no cognitive benefit, showed no antimanic effect, and showed no mania-switch signal that these sample sizes could detect. Larger trials with true placebo control, acute bipolar depression populations, prespecified mania-switch monitoring, and adequate blinding procedures have not been done. Until they are, methylene blue remains an investigational adjunct in this setting, interesting enough to study further and far too thin to support conclusions.